ROCKVILLE, Md. and
SHANGHAI, Aug. 8, 2023
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a
clinical-stage biopharmaceutical company committed to the
discovery, development, and commercialization of pioneering
immunotherapies, today announced that it will report business and
corporate updates and financial results for the six months ended
June 30, 2023, before the market
opens on Thursday, August 17, 2023,
and host a conference call to discuss the results and provide
corporate updates at 8:00 a.m.
EST.
I-Mab Conference Call Information
Investors and analysts are invited to join the conference call
at 8:00 a.m. EST on August 17 via Zoom:
Link:
https://i-mabbiopharma.zoom.us/j/87349766033?pwd=bFhVejFDS1dHeWw3eklaeW1JcFhpUT09
Meeting ID: 873 4976 6033
Password: 194422
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biopharmaceutical
company exclusively focused on bringing transformational medicines
to patients around the world through the discovery, development,
and potential commercialization of novel or highly differentiated
immunotherapies and biologics for oncology. I-Mab's innovative
pipeline, including five key clinical assets and a pipeline of
early-stage clinical and pre-clinical stage drug candidates are
driven by the internal R&D's Fast-to-Proof-of-Concept and
Fast-to-Market development strategies and through global
partnerships. For more information, please
visit http://www.i-mabbiopharma.com and follow us
on LinkedIn, Twitter, and WeChat.
I-Mab Contacts
Investors
|
Media
|
Richard Yeh
Chief Operating
Officer, interim Chief Financial Officer
IR@i-mabbiopharma.com
|
Gigi Feng
Chief Communications
Officer
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-report-mid-year-2023-financial-results-business-and-corporate-updates-on-august-17-2023-301895502.html
SOURCE I-Mab